Sponsor

UCB Japan Co. Ltd.

Clinical research sponsor

Published trials7

Recruiting shown0

Roles2

SourceClinicalTrials.gov

Clinical trials

7 shown

Efficacy and Safety of Olokizumab With Rheumatoid Arthritis With Previously Failed to Anti-tumor Necrosis Factor (Anti-TNF) TherapyNCT01463059 · lead sponsor · 2011-10-01

COMPLETED

Efficacy Confirmation Study of CDP870 in Early Rheumatoid ArthritisNCT01451203 · collaborator · 2011-10-11

COMPLETED

Long-term Treatment Study of CDP870 Self-injection in Patients With Active Rheumatoid Arthritis Who Are Participating in the Long-term Treatment Studies (Study 275-08-002 or Study 275-08-004) of CDP870NCT02586246 · collaborator · 2011-01-01

COMPLETED

Long-term Treatment Study of Certolizumab Pegol Without Coadministration of Methotrexate in Japanese Rheumatoid Arthritis (RA) PatientsNCT00850343 · collaborator · 2009-03-01

COMPLETED

Long-term Treatment Study of Certolizumab Pegol (CDP870) as Add-on Medication to Methotrexate in Japanese Rheumatoid Arthritis (RA) PatientsNCT00851318 · collaborator · 2009-03-01

COMPLETED

Efficacy Confirmation Trial of CDP870 as add-on Medication to Methotrexate (MTX) in Japanese Rheumatoid Arthritis (RA)NCT00791999 · collaborator · 2008-11-01

COMPLETED

Efficacy Confirmation Trial of CDP870 Without Coadministration of Methotrexate (MTX) in Japanese Rheumatoid Arthritis (RA)NCT00791921 · collaborator · 2008-11-01

COMPLETED

Sponsor roles

collaborator6

lead sponsor1

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.